CLENE PROVIDES UPDATE ON ITS NIH-FUNDED EXPANDED ACCESS PROGRAM FOR CNM-AU8® IN ALS (ACT-EAP)
First patient, first visit is planned for early June 2024
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
CLENE ANNOUNCES PUBLICATION OF PHASE 2 CNM-AU8® CLINICAL DATA FOR THE TREATMENT OF ALS IN LANCET’S ECLINICALMEDICINE
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Clene announced that it has entered into a securities purchase agreement with certain existing stockholders.
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results […]
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode
Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022.
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
Clene presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS).
Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
Clene recently announced top-line data from RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS).
